Fig. 4
From: Prenatal muscle development in a mouse model for the secondary dystroglycanopathies
Immunolabelling of laminins α4, α5 γ1 and β1 at E15.5 and P0. Immunolabelling with chain-specific antibodies raised against laminin α4 (A, B, C, D), α5 (E, F, G, H) and γ1 (I, J, K, L), also indicated no clear reduction in FKRPKD relative to wild type at either E15.5 or P0. However, laminin β1 (M, N, O, P) showed a subtle reduction in FKRPKD compared to wild type at E15.5 and P0